PT2142519E - Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade - Google Patents

Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade Download PDF

Info

Publication number
PT2142519E
PT2142519E PT87414488T PT08741448T PT2142519E PT 2142519 E PT2142519 E PT 2142519E PT 87414488 T PT87414488 T PT 87414488T PT 08741448 T PT08741448 T PT 08741448T PT 2142519 E PT2142519 E PT 2142519E
Authority
PT
Portugal
Prior art keywords
dpp
obesity
diabetes
treating
preventing
Prior art date
Application number
PT87414488T
Other languages
English (en)
Portuguese (pt)
Inventor
Heung Jae Kim
Woo Young Kwak
Chang Yell Shin
Hadong Kim
Jong Pil Min
Kyung Jin Park
Jae Young Lee
Song-Hyen Choi
Tae Hyun Yoon
Hae-Sun Kim
Ji Myun Jang
Mi-Kyung Kim
Moon-Ho Son
Soon Hoe Kim
Moohi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of PT2142519E publication Critical patent/PT2142519E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT87414488T 2007-04-19 2008-04-18 Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade PT2142519E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070038462 2007-04-19

Publications (1)

Publication Number Publication Date
PT2142519E true PT2142519E (pt) 2014-12-11

Family

ID=39875638

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87414488T PT2142519E (pt) 2007-04-19 2008-04-18 Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade

Country Status (15)

Country Link
US (1) US8030315B2 (enExample)
EP (1) EP2142519B1 (enExample)
JP (1) JP5148686B2 (enExample)
KR (1) KR101007497B1 (enExample)
CN (2) CN101663282B (enExample)
AU (1) AU2008241692B2 (enExample)
BR (1) BRPI0810246B1 (enExample)
CA (1) CA2683696C (enExample)
ES (1) ES2526338T3 (enExample)
IL (1) IL201524A (enExample)
MX (1) MX2009011276A (enExample)
NZ (1) NZ580701A (enExample)
PT (1) PT2142519E (enExample)
RU (1) RU2419615C1 (enExample)
WO (1) WO2008130151A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
NZ608028A (en) 2009-03-30 2014-09-26 Dong A Pharm Co Ltd Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
BRPI1014070B8 (pt) * 2009-03-30 2021-05-25 Dong A Pharm Co Ltd processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2549997A4 (en) * 2010-03-24 2014-05-14 Dong A Pharm Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS AND METHOD FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS USING THE SAME
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
US20140336196A1 (en) * 2011-05-27 2014-11-13 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
PT3015106T (pt) * 2013-06-26 2021-09-06 Univ Korea Res & Bus Found Composição para prevenção ou tratamento de doenças renais, compreendendo um inibidor da dpp-iv
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
KR101709127B1 (ko) * 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60106607T2 (de) * 2000-05-25 2006-02-09 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
JP4071000B2 (ja) * 2000-05-25 2008-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換１−アミノアルキルラクタム及びムスカリン受容体アンタゴニストとしてのそれらの使用
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
EP1554280B1 (en) * 2002-10-07 2007-08-15 Merck & Co., Inc. Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
ATE390416T1 (de) 2002-10-18 2008-04-15 Merck & Co Inc Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
DE602004018503D1 (de) 2003-07-31 2009-01-29 Merck & Co Inc Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
EP1541143A1 (en) * 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
CA2548918C (en) * 2003-12-11 2013-05-21 Mitsubishi Pharma Corporation Alpha-amino acid derivatives and use thereof as medicines
EP1593671A1 (en) * 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) * 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
US20090124601A1 (en) 2005-03-29 2009-05-14 Song Zhiguo J Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Also Published As

Publication number Publication date
US8030315B2 (en) 2011-10-04
KR20080094604A (ko) 2008-10-23
IL201524A0 (en) 2010-05-31
AU2008241692B2 (en) 2011-02-10
HK1138272A1 (en) 2010-08-20
EP2142519A1 (en) 2010-01-13
ES2526338T3 (es) 2015-01-09
WO2008130151A1 (en) 2008-10-30
CA2683696A1 (en) 2008-10-30
NZ580701A (en) 2011-07-29
EP2142519A4 (en) 2011-07-13
MX2009011276A (es) 2010-01-15
CA2683696C (en) 2012-05-22
AU2008241692A1 (en) 2008-10-30
CN101663282A (zh) 2010-03-03
EP2142519B1 (en) 2014-09-24
CN101663282B (zh) 2012-02-15
JP5148686B2 (ja) 2013-02-20
KR101007497B1 (ko) 2011-01-12
CN102516184A (zh) 2012-06-27
BRPI0810246B1 (pt) 2021-11-30
JP2011500508A (ja) 2011-01-06
CN102516184B (zh) 2015-03-25
IL201524A (en) 2014-09-30
US20100120790A1 (en) 2010-05-13
BRPI0810246A2 (pt) 2015-08-18
RU2419615C1 (ru) 2011-05-27
HK1172613A1 (en) 2013-04-26

Similar Documents

Publication Publication Date Title
PT2142519E (pt) Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
ZA200711040B (en) Method and composition for transdermal drug delivery
IL185761A0 (en) Pharmaceutical compositions for treating diabetes
EP2048153A4 (en) SUBSTITUTED SPIROCETAL DERIVATIVE AND USE THEREOF AS A MEDICAMENT IN THE TREATMENT OF DIABETES
EP2240628A4 (en) RESIN-COATED STEEL SHEET, RESIN COMPOSITION THEREFOR, AND STEEL SHEET TREATMENT COMPOSITION
EP2060949A4 (en) RADIATION-SENSITIVE COMPOSITION AND PROCESS FOR PRODUCING A LOW-MOLECULAR COMPOUND FOR USE THEREIN
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
IL186127A0 (en) A pharmaceutical composition for treating depression and method for preparation thereof
IL188668A0 (en) Daily dosage regimen for treating diabetes, obesity, metabolic syndrome and polycystic ovary syndrome
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
EP2030612A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING COMBUSTIONS (VARIATIONS) AND METHOD FOR THE PRODUCTION THEREOF (VARIANTS)
EP2173825A4 (en) INK COMPOSITION AND METHOD FOR THEIR FORMATION
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
EP2127665A4 (en) MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES
IL185555A0 (en) Method and composition for treating diabetes
EP2125700A4 (en) CALCIUM FUMARATE AND L-CARNITINE, PROCESS FOR THE PREPARATION THEREOF, AND APPLICATIONS THEREOF
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
EP2163244A4 (en) MEDIUM, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING THE DEPENDENCE OF ETHYL ALCOHOL OR NARCOTICS
EP1896038A4 (en) METHOD AND COMPOSITION FOR THE TRANSDERMAL DISTRIBUTION OF MEDICINAL PRODUCTS
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB2435262B (en) Method, composition and articles
ZA200710312B (en) An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating B Cell neoplasm
GB0607562D0 (en) Method, composition and use